Biosyent (Biosyent) Change In Receivables : $0.18 Mil (TTM As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is Biosyent Change In Receivables?

Biosyent's change in receivables for the quarter that ended in Dec. 2023 was $0.46 Mil. It means Biosyent's Accounts Receivable declined by $0.46 Mil from Sep. 2023 to Dec. 2023 .

Biosyent's change in receivables for the fiscal year that ended in Dec. 2023 was $0.18 Mil. It means Biosyent's Accounts Receivable declined by $0.18 Mil from Dec. 2022 to Dec. 2023 .

Biosyent's Accounts Receivable for the quarter that ended in Dec. 2023 was $2.09 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Biosyent's Days Sales Outstanding for the three months ended in Dec. 2023 was 30.87.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Biosyent's liquidation value for the three months ended in Dec. 2023 was $18.24 Mil.

Biosyent Change In Receivables Historical Data

The historical data trend for Biosyent's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biosyent Change In Receivables Chart

Biosyent Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

0.09

0.17

-0.75

-0.31

0.18

Biosyent Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Receivables	Get a 7-Day Free Trial															0.04	-0.18	-0.01	-0.08	0.46

Biosyent Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.18 Mil.

Biosyent (OTCPK:BIOYF) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Biosyent's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	2.086	/	6.167	*	91
=	30.87

2. In Ben Graham's calculation of liquidation value, Biosyent's accounts receivable are only considered to be worth 75% of book value:

Biosyent's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	19.519	-	5.045	+	0.75 * 2.086	+	0.5 * 4.393
=	18.24

Biosyent Change In Receivables Related Terms

Thank you for viewing the detailed overview of Biosyent's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Biosyent (Biosyent) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biosyent Inc (OTCPK:BIOYF) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

RX:Canada

Address

2476 Argentia Road, Suite 402, Toronto, Mississauga, ON, CAN, L5N 6M1

Website

http://www.biosyent.com

Biosyent Inc is a Canada-based growth-oriented specialty pharmaceutical company. It has focused on in-licensing or acquiring originative pharmaceuticals and other healthcare products. Its product includes FeraMAX 150, Cathejell Jelly, FeraMAX Powder, RepaGyn, Proktis-M, Repagyn, and Tibella.